JP2020158544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020158544A5 JP2020158544A5 JP2020115411A JP2020115411A JP2020158544A5 JP 2020158544 A5 JP2020158544 A5 JP 2020158544A5 JP 2020115411 A JP2020115411 A JP 2020115411A JP 2020115411 A JP2020115411 A JP 2020115411A JP 2020158544 A5 JP2020158544 A5 JP 2020158544A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- day
- once daily
- μci
- venetoclax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023168404A JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
| JP2025202062A JP2026026133A (ja) | 2017-04-28 | 2025-11-21 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491803P | 2017-04-28 | 2017-04-28 | |
| US62/491,803 | 2017-04-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558417A Division JP2020517704A (ja) | 2017-04-28 | 2018-04-26 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023168404A Division JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020158544A JP2020158544A (ja) | 2020-10-01 |
| JP2020158544A5 true JP2020158544A5 (https=) | 2022-09-16 |
Family
ID=63919290
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558417A Withdrawn JP2020517704A (ja) | 2017-04-28 | 2018-04-26 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2020115411A Withdrawn JP2020158544A (ja) | 2017-04-28 | 2020-07-03 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| JP2023168404A Withdrawn JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
| JP2025202062A Pending JP2026026133A (ja) | 2017-04-28 | 2025-11-21 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558417A Withdrawn JP2020517704A (ja) | 2017-04-28 | 2018-04-26 | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023168404A Withdrawn JP2023165952A (ja) | 2017-04-28 | 2023-09-28 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
| JP2025202062A Pending JP2026026133A (ja) | 2017-04-28 | 2025-11-21 | α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11364235B2 (https=) |
| EP (1) | EP3615047A4 (https=) |
| JP (4) | JP2020517704A (https=) |
| CN (1) | CN110612109A (https=) |
| BR (1) | BR112019022308A2 (https=) |
| CA (1) | CA3059752A1 (https=) |
| MX (1) | MX2019012660A (https=) |
| WO (1) | WO2018200841A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020517704A (ja) | 2017-04-28 | 2020-06-18 | アクティニウム ファーマシューティカルズ インコーポレイテッド | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| US20230132400A9 (en) * | 2017-11-10 | 2023-04-27 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| WO2020142583A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| AU2021206233A1 (en) * | 2020-01-10 | 2022-08-11 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
| US20240299600A1 (en) * | 2020-09-08 | 2024-09-12 | Actinium Pharmaceuticals, Inc. | Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6683162B2 (en) * | 2000-09-15 | 2004-01-27 | Sloan Kettering Institute Of Cancer Research | Targeted alpha particle therapy using actinium-255 conjugates |
| US8487131B2 (en) * | 2009-04-15 | 2013-07-16 | Sanford-Burnham Medical Research Institute | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI719942B (zh) * | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| JP6961490B2 (ja) * | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| ES2965461T3 (es) * | 2015-08-03 | 2024-04-15 | Biokine Therapeutics Ltd | Inhibidor de CXCR4 para el tratamiento del cáncer |
| JP2020517704A (ja) * | 2017-04-28 | 2020-06-18 | アクティニウム ファーマシューティカルズ インコーポレイテッド | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
-
2018
- 2018-04-26 JP JP2019558417A patent/JP2020517704A/ja not_active Withdrawn
- 2018-04-26 US US16/607,168 patent/US11364235B2/en active Active
- 2018-04-26 MX MX2019012660A patent/MX2019012660A/es unknown
- 2018-04-26 CN CN201880027661.XA patent/CN110612109A/zh active Pending
- 2018-04-26 WO PCT/US2018/029607 patent/WO2018200841A1/en not_active Ceased
- 2018-04-26 EP EP18792272.9A patent/EP3615047A4/en active Pending
- 2018-04-26 CA CA3059752A patent/CA3059752A1/en active Pending
- 2018-04-26 BR BR112019022308-8A patent/BR112019022308A2/pt unknown
-
2020
- 2020-07-03 JP JP2020115411A patent/JP2020158544A/ja not_active Withdrawn
-
2022
- 2022-05-16 US US17/745,045 patent/US11844799B2/en active Active
-
2023
- 2023-09-28 JP JP2023168404A patent/JP2023165952A/ja not_active Withdrawn
- 2023-11-02 US US18/500,735 patent/US12133849B2/en active Active
-
2024
- 2024-09-30 US US18/901,169 patent/US20250017919A1/en active Pending
-
2025
- 2025-11-21 JP JP2025202062A patent/JP2026026133A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020158544A5 (https=) | ||
| ES2543383T3 (es) | Tratamiento de tumores de mama con un derivado de rapamicina en combinación con exemestano | |
| JP2022525149A5 (https=) | ||
| JP2020517704A5 (https=) | ||
| JP2022160685A5 (https=) | ||
| JP2024518947A5 (https=) | ||
| JP2023540795A5 (https=) | ||
| Shin et al. | Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2024530189A5 (https=) | ||
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| JP2021535161A5 (https=) | ||
| Silberstein et al. | Early onset of efficacy and consistency of response across multiple migraine attacks from the randomized COMPASS study: AVP‐825 breath powered® exhalation delivery system (sumatriptan nasal powder) vs oral sumatriptan | |
| CN104039148A (zh) | 组合als疗法 | |
| JP2024016209A5 (https=) | ||
| JPWO2020250915A5 (https=) | ||
| JP2022548575A5 (https=) | ||
| US20200071415A1 (en) | Combination therapy for pancreatic cancer | |
| JP2021502347A5 (https=) | ||
| JP2021004249A5 (https=) | ||
| Luqmani | Discontinuation of therapies in vasculitis | |
| JP2024535880A5 (https=) | ||
| JP2021535163A5 (https=) | ||
| MX2024008330A (es) | Combinacion de obicetrapib e inhibidor de sglt2 | |
| Trobe | High-dose corticosteroid regimen retards development of multiple sclerosis in optic neuritis treatment trial |